GXGuifeng Xu

Guifeng Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guifeng Xu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Hanping Li

    Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, P.R. China

    1 shared publication
  • Jieling Li

    Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    1 shared publication
  • Jiyan Chen

    Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangzhou, 510080, P.R. China

    1 shared publication
  • Ju-E Liu

    Department of Pharmacy, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, P.R. China

    1 shared publication
  • Kai Zheng

    School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China

    1 shared publication
  • Ling Ou

    School of pharmaceutical sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China

    1 shared publication

Latest Publications

  • DNA Methylation Mediates the Genetic Variants on Ticagrelor Major Metabolite Elimination and Platelet Function Recovery after Ticagrelor Discontinuation

    by Guifeng Xu, Ju-E Liu, Xiaoqi Liu, Wanping Zhong, Zixian Wang, Hanping Li, Xiao Xiao, Jiyan Chen, Shilong Zhong, Weihua Lai

    Aim: To investigate the influence of DNA methylation on ticagrelor major metabolite M8 elimination and platelet function recovery after ticagrelor discontinuation. Materials & methods: Among health...

  • Open Access

    Upregulation of Centromere Proteins as Potential Biomarkers for Esophageal Squamous Cell Carcinoma Diagnosis and Prognosis

    by Xiao Wang, Minshan Lai, Yue Wang, Ruihuan Chai, Nan Li, Ling Ou, Kai Zheng, Jieling Li, Guifeng Xu, Shaoqi Wang, et al.

    Esophageal squamous cell carcinoma (ESCC) has a high incidence and low survival rate, necessitating the identification of novel specific biomarkers. Centromere-associated proteins (CENPs) have been reported to be biomarkers for many cancers, but their roles in ESCC have seldom been investigated. Here, the potential clinical roles of CENPs in ESCC patients were demonstrated by a systematic bioinformatics analysis. Most CENP-encoding genes were differentially expressed between tumor and normal tissues. CENPA, CENPE, CENPF, CENPI, CENPM, CENPN, CENPQ, and CENPR were upregulated universally in the three datasets. Survival analysis demonstrated that high expression of CENPE and CENPQ was positively correlated with the outcomes of ESCC patients. The CENPE-based forecast model was more accurate than the tumor-node-metastasis (TNM) staging-based model, which was classified as stage I/II vs. III/IV. More importantly, the forecast model based on the commonly upregulated CENPs exhibited a much higher area under the curve (AUC) value (0.855) than the currently known TTL, ZNF750, AC016205.1, and BOLA3 biomarkers. The nomogram model integrating the CENPs, TNM stage, and sex was highly accurate in the prognosis of ESCC patients ( ). Besides, gene set enrichment analysis (GSEA) demonstrated that CENPE expression is significantly correlated with cell cycle, G2/M checkpoint, mitotic spindle, p53, etc. Finally, in validation experiments, we also found that CENPE and CENPQ were significantly overexpressed in esophageal cancer cells. Taken together, these results clearly suggest that CENPs are clinically promising diagnostic and prognostic biomarkers for ESCC patients.